MarketScreener Homepage > Equities > Nasdaq > Galapagos NV GLPG

Report

Delayed Nasdaq - 01/15 04:00:00 pm
100.01	USD		-1.68%

01/12

GALAPAGOS NV : - Gilead holds 25.54% of Galapagos shares

01/11

Gilead holds 25.54% of Galapagos shares

01/06

GALAPAGOS : to present at 39th Annual J.P. Morgan Healthcare Conference

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

01/11/2021	01/12/2021	01/13/2021	01/14/2021	01/15/2021	Date
103.02(c)	102.55(c)	100.51(c)	101.72(c)	100.01(c)	Last
208 145	131 335	163 690	132 528	371 804	Volume
-0.40%	-0.46%	-1.99%	+1.20%	-1.68%	Change

More quotes

Financials

Sales 2020	501 M 605 M 605 M
Net income 2020	-322 M -388 M -388 M
Net cash position 2020	3 913 M 4 725 M 4 725 M
P/E ratio 2020	-19,2x
Yield 2020	-

Sales 2021	503 M 608 M 608 M
Net income 2021	-379 M -458 M -458 M
Net cash position 2021	3 494 M 4 219 M 4 219 M
P/E ratio 2021	-18,8x
Yield 2021	-

Capitalization	5 391 M 6 518 M 6 510 M
EV / Sales 2020	2,95x
EV / Sales 2021	3,77x
Nbr of Employees	1 407
Free-Float	73,8%

More Financials

Company

Galapagos NV specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales break down by activity as follows: - discovery and development of drugs (98.8%); - other (1.2%). Net sales are distributed geographically as follows: Europe (5.8%) and North America (94.2%).

Sector

Biotechnology & Medical Research

Calendar

01/14 | 09:10am

Presentation

More about the company

Notations Surperformance© of Galapagos NV

Trading Rating :

Investor Rating :

More Ratings

All news about GALAPAGOS NV

01/12	GALAPAGOS NV : - Gilead holds 25.54% of Galapagos shares	AQ
01/11	Gilead holds 25.54% of Galapagos shares	GL
01/06	GALAPAGOS : to present at 39th Annual J.P. Morgan Healthcare Conference	AQ
01/04	Selvita completes acquisition of Fidelta from Galapagos	GL
2020	Galapagos Shares Drop 19% After Gilead Won't Seek FDA Approval for Jyseleca	DJ
2020	GILEAD SCIENCES : and Galapagos Announce New Commercialization and Development A..	AQ
2020	GLOBAL MARKETS LIVE : Moderna, Google, Twitter….
2020	Gilead, Galapagos Amend Arrangement on Jyseleca; Gilead Won't Pursue FDA Appr..	DJ
2020	Upbeat business activity, vaccine hopes lift European shares	RE
2020	GALAPAGOS : Gilead Abandon US FDA Application for Arthritis Treatment	MT
2020	GILEAD SCIENCES : says not to pursue U.S. approval for rheumatoid arthritis drug	RE
2020	GILEAD SCIENCES : abandons filgotinib for rheumatoid arthritis in U.S.	RE
2020	GALAPAGOS : Gilead and Galapagos Announce New Commercialization and Development ..	BU
2020	Gilead and Galapagos announce New Commercialization and Development A..	GL
2020	SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..	PR

More news

News in other languages on GALAPAGOS NV

01/07	AVIS D'ANALYSTES DU JOUR : Amadeus, Aston Martin, Atos, EDF, Galapagos, Inficon,..
2020	AVIS D'ANALYSTES DU JOUR : ABB, Delta Plus, EDP, Galapagos, HelloFresh, Sika, Ve..
2020	AVIS D'ANALYSTES DU JOUR : ArcelorMittal, ASML, BioMérieux, Flatex, HelloFresh, ..
2020	EN DIRECT DES MARCHES : Atos, Crédit Agricole, Eramet, Valneva, Nanobiotix, Goog..
2020	AVIS D'ANALYSTES DU JOUR : Amadeus, Cellnex, Eurazeo, Givaudan, Kering, Klépierr..

More news

Analyst Recommendations on GALAPAGOS NV

2020	Maxim Group Initiates Coverage on Galapagos NV With Buy Rating, $170 Price Ta..	MT
2020	JPMorgan Adjusts Galapagos NV's Price Target to 120 Euros From 130 Euros, Mai..	MT
2020	Credit Suisse Adjusts Galapagos' Price Target to 105 Euros from 129 Euros, Ke..	MT

More recommendations

Provided by Scoopnest.com

Chart GALAPAGOS NV

Duration : Period :

Galapagos NV Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends GALAPAGOS NV

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bearish	Bearish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	HOLD
Number of Analysts	11
Average target price	94,40 €
Last Close Price	82,42 €
Spread / Highest target	51,7%
Spread / Average Target	14,5%
Spread / Lowest Target	-10,2%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Onno van de Stolpe	Chief Executive Officer & Executive Director
Raj B. Parekh	Chairman
Bart Filius	Chief Operating & Financial Officer
Piet Wigerinck	Chief Scientific Officer
Walid Abi-Saab	Chief Medical Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

GALAPAGOS NV	1.04%	6 518



MODERNA, INC.	24.10%	51 332
LONZA GROUP AG	3.31%	49 176
CELLTRION, INC.	-8.36%	43 849
IQVIA HOLDINGS INC.	4.81%	36 066
SEAGEN INC.	6.06%	31 812

More Results